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Abstract As part of its Medical Technology Evaluation
Programme, the National Institute for Health and Care
Excellence (NICE) invited a manufacturer to provide
clinical and economic evidence for the evaluation of the
Debrisoft monofilament debridement pad for use in acute
or chronic wounds. The University of Birmingham and
Brunel University, acting as a consortium, was commis-
sioned to act as an External Assessment Centre (EAC) for
NICE, independently appraising the submission. This
article is an overview of the original evidence submitted,
the EAC’s findings and the final NICE guidance issued.
The sponsor submitted a simple cost analysis to estimate
the costs of using Debrisoft to debride wounds compared
with saline and gauze, hydrogel and larvae. Separate
analyses were conducted for applications in home and
applications in a clinic setting. The analysis took an UK
National Health Service (NHS) perspective. It incorporated
the costs of the technologies and supplementary technolo-
gies (such as dressings) and the costs of their application by
a district nurse. The sponsor concluded that Debrisoft was
cost saving relative to the comparators. The EAC made
amendments to the sponsor analysis to correct for errors
and to reflect alternative assumptions. Debrisoft remained
cost saving in most analyses and savings ranged from £77
to £222 per patient compared with hydrogel, from £97 to
£347 compared with saline and gauze, and from £180 to
£484 compared with larvae depending on the assumptions
included in the analysis and whether debridement took
place in a home or clinic setting. All analyses were
severely limited by the available data on effectiveness, in
particular a lack of comparative studies and that the
effectiveness data for the comparators came from studies
reporting different clinical endpoints compared with
Debrisoft. The Medical Technologies Advisory Com-
mittee made a positive recommendation for adoption of
Debrisoft and this has been published as a NICE medical
technology guidance (MTG17).
Key Points for Decision Makers
Debrisoft is convenient and easy to use, is well-
tolerated by adults and children, and can result in
quicker debridement of chronic or acute wounds
with fewer nurse visits needed than other
debridement methods. Debridement is an important
component of standard wound care management, as
described in clinical guidelines on pressure ulcers
[National Institute for Health and Care Excellence
(NICE) clinical guideline 179] and diabetic foot
problems (NICE clinical guideline 119).
Debrisoft is estimated to be cost saving for
complete debridement compared to other methods
such as hydrogel, gauze and bagged larvae.
1 Introduction
The National Institute for Health and Care Excellence
(NICE) produces evidence-based medical technologies
guidance with the overall aim of evaluating, and where
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appropriate encouraging, the adoption of novel and inno-
vative medical devices and diagnostics within the National
Health Service (NHS) in England. Manufacturers or dis-
tributors of potentially eligible technologies notify their
products to NICE’s Medical Technologies Evaluation
Programme (MTEP). Technologies are selected for evalu-
ation by MTEP if they have the potential to offer signifi-
cant clinical benefits to patients and the NHS or reduce the
cost compared with current standard practice. Guidance is
produced after clinical and cost evidence submitted by the
sponsor is independently assessed by an External Assess-
ment Centre (EAC) and after a public consultation period.
Devices and diagnostic tools with more complex value
propositions can be routed for evaluation through other
NICE programmes such as the Diagnostics Assessment
Programme or Technology Appraisals. Campbell and
Campbell (2012) describe the methods of MTEP in more
detail [1].This article presents a summary of the EAC
report for the Debrisoft monofilament debridement pad
(Lohmann & Rauscher GmbH & Co. KG, Neuwied, Ger-
many) for use in acute or chronic wounds. It is part of a
series of NICE Medical Technology Guidance summaries
being published in Applied Health Economics and Health
Policy [2, 3].
2 Background to the Condition and its Treatment
Skin wounds are a very common condition and can be
acute or chronic. Acute wounds occur from cuts, burns,
abrasions or pressure on the skin. Some acute wounds
become chronic, particularly if there is underlying pathol-
ogy, e.g. diabetes mellitus or poor venous drainage.
Chronic wounds include pressure ulcers, diabetic foot
ulcers, and venous and arterial leg ulcers.
In the UK in 2008, approximately 200,000 people had
chronic wounds. These wounds include leg, pressure and
foot ulcers [4]. Leg ulcers affect 1 in 500 people, although
this rises sharply with an increase in age, to 1 in 50 in those
over the age of 80 years [5]. In the UK, the annual inci-
dence for foot ulcers among people with diabetes is 2–5 %,
with the annual incidence of amputation being 0.25–1.8 %
[6]. Approximately 10 % of all leg ulcers are caused by
arterial ulcers.
Lymphoedema is a chronic condition that is charac-
terised by oedema. Primary lymphoedema, an inherited
condition, occurs in 1 in 10,000 people and mainly affects
the legs, whereas secondary lymphoedema, caused by an
injury to the lymph system, affects approximately 100,000
people in total in the UK [7] and can affect the legs and
arms, depending on cause.
In any given year, just under half a million people in the
UK will developing at least one pressure ulcer, usually
people with an underlying health condition. Around 1 in 20
people who are admitted to hospital with an acute (sudden)
illness will develop a pressure ulcer [8].
Debridement is the removal of devitalised, contaminated
or foreign material from the surface of a wound with the
intension to expose healthy tissue. The main methods of
debridement are mechanical, sharp, larvae (loose or bag-
ged), autolytic, enzymatic or surgical. These methods have
different characteristics, speeds of conduct, advantages and
disadvantages, and can be conducted by different groups of
healthcare professionals (see Table 1). It is widely believed
that wound healing is enhanced by the practice of
debridement, but there is little conclusive proof. An early
health technology assessment found no randomised con-
trolled trials (RCTs) comparing debridement to no
debridement in chronic wounds [9], but a more recent
review on debridement methods has shown there may be
some RCTs [10], although the descriptions of the primary
study control groups in this review are unclear. A recent
Cochrane review on debridement in diabetic foot ulcers has
claimed that direct evidence on debridement versus no
debridement is lacking [11]. There have been no large,
good-quality RCTs of debridement versus no debridement
in any acute or chronic wounds, so whether it is beneficial
or not in acute or chronic wounds is unclear. RCTs found
include one on surgical debridement in chronic venous
ulcers which showed that 16 % of 28 ulcers had complete
healing in the debridement group compared with 4.3 % of
27 ulcers in the control group [12]. Another on surgical
debridement [13] found that 21 of 22 (95 %) ulcers treated
with surgical debridement had completely healed within
6 months, compared with 19 of 24 (79 %) in the conser-
vative care group. An early RCT on debridement versus no
debridement in acute wounds (gunshot) found that slightly
more patients in the debridement group (4 of 89) got
wound infections than those in the control group (2 of 74)
[14]. A recent US cohort study of a large number of
patients with a variety of mainly chronic wounds found that
those wounds receiving more frequent debridement had
faster healing rates on average [15]. However, the results
may be confounded by a variety of factors such as patient
characteristics, nursing care experienced and debridement
methods used. Nevertheless, it seems to be generally
accepted by most wound care practitioners that debride-
ment is mostly beneficial.
With regard to effectiveness of debridement, good
comparative evidence does exist on the comparators, e.g. is
a large cohort study was published recently of 312,744
wounds (154,664 patients, median age 69 years) looking at
frequency of debridement and time to heal [15]. The
debridement methods included autolytic, enzymatic,
mechanical, surgical and biosurgical (larvae). The wound
types were a wide variety of chronic wounds. The study
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found that more debridements per wound resulted in faster
healing times. A Cochrane review of debridement of dia-
betic foot ulcers [11] included RCTs on larvae compared
with hydrogel [16] and hydrogel compared with gauze/s-
tandard care [17–19]. A Cochrane review of debridement
of surgical wounds [20] included RCTs of hydrogel com-
pared with gauze [21, 22].
3 The Decision Problem
3.1 Population
The target population was adults or children requiring
debridement of an acute or chronic wound in a community-
based setting. The skin could be intact (closed wounds) or
non-intact (open wounds). The sponsor evaluated adults
with chronic wounds and did not investigate the subgroup
of open and closed wounds. There was a considerable lack
of clarity over normal debridement practice in a standard
NHS community setting.
3.2 Intervention
The intervention was Debrisoft monofilament debride-
ment pad, which is a square pad measuring 10 9 10 cm
that has monofilament polyester fibres projecting from the
wound contact side, making it feel soft and fleecy. The pad
is used when moistened with water and is gently rubbed
over wound or skin surfaces, and is intended to facilitate
the removal of dead or damaged tissue, etc. The claimed
benefits of Debrisoft include reduction in pain, improved
acceptability, faster treatment and healing, reduced risks of
trauma to healthy tissue, and of bleeding, reduced time and
resources needed, lower costs and shorter waiting times,
more effective debridement, improved patient concordance
and avoidance of ongoing costs relating to specialist
methods of debridement.
3.3 Comparators
The scope comparators were hydrogels or other autolytic
dressings, or cleansing with gauze. The sponsor also
evaluated the use of larvae. It was unclear whether the
gauze use was wet to dry debridement or just wet
cleansing.
3.4 Outcomes
Outcomes, including surrogate outcomes, listed in the
scope included wound healing, quality of life, time to
complete debridement, number of debridements required,
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and the need to refer to a tissue viability nurse or hospital
specialist clinic. Adverse effects included pain, wound
infections, cellulitis and trauma to healthy tissue.
4 Review of the Clinical and Economic Evidence
The sponsor submitted clinical and economic evidence
based on the scope issued by NICE. The economic evi-
dence included a de novo economic model. The EAC
critically appraised the submission and carried out addi-
tional analyses to evaluate the outcomes identified in the
scope.
4.1 Clinical Effectiveness Evidence
4.1.1 Sponsor’s Review of Clinical Effectiveness Evidence
The sponsor submitted 51 studies in the qualitative syn-
thesis. However, many of these were single case studies or
testimonials, some within larger documents. They included
eight journal articles, 28 conference posters and two
advertising reports sponsored by the company that included
multiple case studies. There were several multiple patient
case series submitted. Bahr et al. [23] and Mustafi et al.
[24] compared the overall mean time of each debridement
session, using the Debrisoft pad, with hydrogel, gauze and
surgical debridement in 60 patients. Gray et al. [25]
described a case series of 18 patients that evaluated which
types of slough and necrotic tissue benefit most from
debridement with the Debrisoft pad. Haemmerle et al.
[26] described a case series of 11 patients with chronic
wounds from two hospitals. Johnson et al. [27] described a
two-centre observational study that compared the effec-
tiveness of the Debrisoft pad with other non-specified
debridement methods. Ten patients were recruited from
each centre. Stephen-Haynes and Callaghan [28] evaluated
the use of the Debrisoft pad by 40 tissue viability nurses,
over a 12-week period, on a wound or hyperkeratosis.
4.1.2 Critique of Clinical Effectiveness Evidence
As the claimed benefits for Debrisoft were all compara-
tive statements, only evidence with comparators was
evaluated. These were journal articles by Bahr et al. [23]
and Johnson et al. [27], and conference posters by Cal-
laghan and Stephen-Haynes [29], Collarte [30], Mustafi
et al. [24], Pietroletti et al. [31] and Wiser [32]. The
characteristics of these studies are in Table 2.
An attempt was made to match the claimed benefits of
Debrisoft to the comparative evidence available. Table 3
shows all of the numerical comparative results found.
Some of the included studies reported comparative results
narratively. Wiser [32] reported reduction of pain, more
effective debridement and improved acceptability with
Debrisoft compared with saline soaks. Collarte [30]
reported a decreased time to treat with Debrisoft com-
pared with standard treatment (not otherwise specified) and
that autolytic debridement took significantly longer. Col-
larte also reported that Debrisoft removed more devi-
talised tissue and hyperkeratosis more quickly. Callaghan
and Stephen-Haynes [29] reported a reduction in wound
care visits for Debrisoft, but it was not clear what the
comparator was. They also reported that there were sig-
nificant differences compared with gauze and sharp
debridement. Pietroletti et al. [31] reported that Debrisoft
was not as expensive as current debridement methods (not
otherwise specified).
The comparative evidence suggested that Debrisoft
was associated with less pain, improved acceptability by
patients, decreased time to treat, reduction in wound care
visits, more removal of devitalized tissue and more effec-
tive debridement than standard treatment, previous meth-
ods (not specified), gauze, autolytic, enzymatic or sharp/
scalpel debridement. There was no comparative evidence
on larvae found. It can be seen that there is no comparative
information on most of the claimed benefits, particularly
healing rates, compared with the comparators listed in the
scope and to larvae (see Table 3). There was no useful
evidence on the rate of wound healing or wound infections.
There was no information on the mean number of appli-
cations required with Debrisoft to achieve complete
debridement.
No comparative results on adverse events were pre-
sented by the sponsor. It is currently unclear if use of
Debrisoft is associated with higher rates of wound
infections than the comparators of gauze, hydrogel or lar-
vae. It is also unclear if use of Debrisoft is associated with
higher or lower rates of pain in the patient than the com-
parators of gauze, hydrogel or larvae. The NICE expert
advisers have not voiced a clear opinion about adverse
events with the use of Debrisoft compared with the
comparators of gauze, hydrogel or larvae.
4.2 Economic Evidence
4.2.1 Sponsor’s Economic Submission
The sponsor conducted a systematic search of economic
evidence from the literature but this did not identify any
studies reporting data on the costs or cost effectiveness of
Debrisoft. In the absence of an appropriate published
analysis, the sponsor submitted a de novo analysis using a
simple cost model executed in Microsoft Excel. The
model estimated the cost and resource consequences of
Debrisoft used in a community setting compared with

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































588 C. Meads et al.
hydrogel, gauze and larvae. Separate analyses were con-
ducted for applications in home and clinic settings. All
analyses were based on an NHS perspective. No distinction
was made between adults and children, or between chronic
and acute wounds.
The stated time horizon of the analysis was to complete
debridement. The clinical pathway reflected in the model
included the following five stages: (1) an assessment of the
skin and wound by a district nurse; (2) ordering the
debridement agent if not available to the district nurse
immediately; (3) application of the debridement agent by a
district nurse; (4) re-assessment of the wound; and (5)
further applications of the debridement agents until
debridement is judged to be complete.
The effectiveness data used in the analysis came from
three separate sources (see Table 4). Data on the mean
number of applications to achieve wound healing from a
published randomised trial were used to inform the effec-
tiveness of larvae and hydrogel [33, 34]. The effectiveness
of Debrisoft was based on the percentage of wounds
completely debrided after three applications as reported in
the case series study by Bahr et al. [23]. This reported that
77 % of wounds were completely debrided with Debrisoft
after three applications. For gauze, the effectiveness data
were based on clinical opinion of the number of applica-
tions required to achieve complete debridement. A sum-
mary of the effectiveness data used in the model is
presented in Table 4. The model did not include adverse
events associated with any of the technologies.
Given the differences in outcomemeasures used to inform
clinical effectiveness in the model, particularly the lack of
data on the mean number of applications for Debrisoft to
achieve debridement, the sponsor employed a ‘stopping rule’
forDebrisoft in the analysis. This assumed that if thewound
was not completely debrided after three applications of
Debrisoft, patients would switch to the use of hydrogel for
complete debridement. No stopping rule was employed for
the other debridement agents.
Resource use included the debridement agents (De-
brisoft, hydrogel, gauze and larvae), supplementary
technologies (cover dressings: film and absorbent dress-
ings; dressing packs) and district nurse visits (at home or
clinic). The amount of debridement agents required was
based on the amount needed to debride a wound of
10 9 10 cm. The cost of larvae was based on the costs of
loose larvae and obtained directly from a supplier. The cost
of hydrogel was based on the median cost of all formula-
tions listed in the British National Formulary (BNF) [35].
Unit costs were obtained from published sources and were
expressed in 2012–2013 Great Britain pounds sterling
(reported in Table 5).
The number of visits by a district nurse required to apply
the debridement agent varied according to setting (clinic or
home) and comparator. The number and length of district
Table 4 Amount and unit cost of each debridement product
Comparator Number of applications to complete debridement Cost per application
n Source Cost (£) Source
Debrisoft 3 Bahr et al. [23] 6.19 BNF 2012 [35] (A5.5.3)
Loose larvae 1.45 Soares et al. [36] 175.00 Biomonde, data on file, 2013
Bagged larvae 1.45 Soares et al. [36] 295.00 Biomonde, data on file, 2013
Hydrogel 9.2 Soares et al. [36] 2.03 BNF 2012 [35] (median price) (A5.2.1)
Gauze 12 Clinical opinion 0.39 BNF 2012 [35] (A5.7.2)
BNF British National Formulary
Table 5 Summary of unit cost estimates in the sponsor’s economic model
Resource Unit cost (£) Source
District nurse (15 min—clinic visit) 12.75 PSSRU costs for community nurse—sponsor calculation
District nurse (15 min—home visit) 24.25 PSSRU costs for home visit community nurse—sponsor calculation
District nurse (15 min—clinic visit) 14.50 PSSRU costs for community nurse—EAC calculation
District nurse (15 min—home visit) 17.50 PSSRU costs for home visit by community nurse—EAC calculation
Dressing pack (all comparators/settings) 0.60 BNF 2012 [35]
Secondary dressing (for larvae and gauze) 0.17 BNF 2012 [35]
Secondary dressing (for hydrogel) 1.02 BNF 2012 [35]
BNF British National Formulary, EAC External Assessment Centre, PSSRU Personal And Social Services Research Unit
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nurse visits were based on expert opinion. Gauze (clinic
and home settings) and hydrogel (clinic setting only) are
assumed to be available to the nurse immediately and
require a total of two visits for the first application (one to
assess the wound and apply the debridement product; the
second to reassess the wound and reapply the product if
needed) plus one visit for each subsequent application. It
was assumed that hydrogel would require ordering by the
district nurse in the home setting following the initial
assessment, similar to larvae in both the home and clinic
settings. Therefore, additional visits are included for the
first application of hydrogel in the home setting and for the
first and all sequent applications of larvae in the home and
clinic settings. All district nurse visits were assumed to last
15 min.
The sponsor conducted deterministic sensitivity analy-
ses on the number of debridement applications, the number
of district nurse visits and unit costs of debridement agents
(all increased and decreased by an arbitrary 20 %). Prob-
abilistic analyses were not presented.
The baseline results of the sponsor’s analysis are pre-
sented in Table 6. Debrisoft was cost saving compared
with all three comparators in both the home and clinic
settings. Debrisoft remained cost saving in all sensitivity
analyses.
4.2.2 Critique of Economic Evidence
Overall, the pathway of care reflected in the sponsor’s
economic model appeared to be appropriate. The time
horizon of the analysis was until debridement rather than to
wound healing, which may have been a more meaningful
endpoint as it could reflect that some wounds will require
multiple debridements. Time to wound healing has been
used as the endpoint in previous clinical trials of debride-
ment, including the main source of effectiveness used in
the sponsor’s analysis for hydrogel and larvae [33].
The main drivers of the cost analysis were the number of
applications required to debride the wound and number of
visits required per application for each product. Although
the stated time horizon was until complete debridement,
the effectiveness data used for two of the comparators in
the analysis (larvae and hydrogel) did not reflect this
endpoint. The data on the number of applications for larvae
and hydrogel came from a randomised clinical trial of the
products with a primary endpoint of wound healing and an
average follow-up of 1 year. The data from these studies
used in the analysis reflected the average number of
applications until wound healing rather than the number of
applications to achieve complete debridement. The effec-
tiveness data used for Debrisoft were not comparable and
based on the percentage of wounds successfully debrided
after three applications at 12 days of follow-up from the
case series study [23]. This study found that 77 % of
wounds were completely debrided at 12 days; however,
following clarification, the sponsor confirmed that this
endpoint was not pre-specified in the analysis plan for the
trial. This lack of information from a direct comparison or
network meta-analysis for the main effectiveness data used
in the economic analysis is likely to lead to bias in the
comparison of the number of applications for each of the
products; however, it is difficult to judge the likely impact
of this on the results.
To compensate for the lack of comparability in the
effectiveness outcomes used in the analysis, the sponsor
employed a ‘stopping rule’ for Debrisoft. The advice
from a NICE clinical expert was that two to three appli-
cations of Debrisoft would usually be required to debride
Table 6 Results of the
economic analyses (in
2012/2013 British pounds; £)
Saline and gauze Hydrogel Larvae Debrisoft
Home Clinic Home Clinic Home Clinic Home Clinic
Sponsor’s base case
Cost of debridement 330 180 308 165 351 306 162 83
Debrisoft incremental cost -168 -97 -147 -82 -190 -223
EAC corrected analysis
Cost of debridement 242 203 233 183 325 313 145 106
Debrisoft incremental cost -98 -97 -88 -77 -180 -207
EAC amendments
Cost of debridement 621 291 544 238 613 514 333 139
Debrisoft incremental cost -288 -152 -211 -99 -280 -375
Committee-requested analysis
Cost of debridement 621 291 497 238 744 623 275 139
Debrisoft incremental cost -347 -152 -222 -99 -469 -484
EAC External Assessment Centre
590 C. Meads et al.
a hard eschar, and one application for a sloughy wound.
Based on this advice, the assumptions around the number
of applications of Debrisoft per debridement may be
reasonable.
The time taken by the district nurse visit was based on
advice from clinical experts and differs to estimates
reported in a randomised trial of hydrogel and larvae in
which the length of appointments was measured directly
[36]. This trial reported the average duration of clinic visits
to be 22 and 40 min for home visits.
The costs of larvae included in the analysis are based on
the costs of loose larvae. Advice from a NICE clinical
advisor was that bagged larvae would be used in UK
clinical practice. This would have the effect of making
larvae more expensive relative to Debrisoft.
Further alternative feasible assumptions around the
amount and costs of dressings could have been included in
the sponsor’s analysis. Additional film and absorbent
dressings would not be required prior to debridement,
specifically at the first appointment if the debridement
product has to be ordered by the district nurse. Also, the
unit costs for these dressings, gauze and hydrogels were
based on the median unit costs for each type of technology
listed in the BNF. We considered that, given the assump-
tion of equal efficacy in the model, it would be appropriate
to use the lowest unit cost for each technology to reflect
cost-effective practice.
4.2.3 Supplementary Economic Analyses Conducted
by the External Assessment Centre
Upon review of the economic model, the EAC identified
some errors in the sponsor’s analysis. These included the
incorrect implementation of the stopping rule for
Debrisoft and a miscalculation in the unit costs of a dis-
trict nurse visit at home. The estimates of the district nurse
costs appear to have come from a misunderstanding
regarding the apportionment of travel costs and the unit
costs for nurses with qualifications in the original esti-
mates. The results of the cost analysis after correcting these
errors are presented in Table 6 (‘EAC corrected analysis’).
Further changes were made by the EAC to reflect
alternative assumptions in the economic model. Firstly, the
costs of larvae were amended to the bagged variety. Sec-
ondly, the costs of additional dressings when patients did
not undergo debridement were removed. Thirdly, the time
taken for each district nurse visit was amended to that
reported in the published trial of hydrogel and larvae [36].
Finally, the unit costs of dressings, gauze and hydrogels
were amended to the cheapest listed in the BNF. The
impact of all of these changes on the results is shown in
Table 6 (‘EAC amendments’). The use of the costs of
bagged larvae led to a substantial increase in the costs of
this comparator relative to Debrisoft. The amendments to
the nursing time also had an impact on the results,
increasing the estimated cost savings for Debrisoft rela-
tive to gauze and hydrogel, particularly in the home setting.
The other amendments to the dressings had only a marginal
impact.
The EAC also conducted further exploratory analyses.
These included removing the stopping rule from the analysis
and a threshold analysis to assess how many applications of
Debrisoft would be required for it to no longer be the
cheapest option, keeping all other variables constant. The
starting point for these analyses was the analysis after cor-
recting for errors and employing alternative assumptions
(‘EAC amendments’). We found that, without the stopping
rule, Debrisoftwould no longer be the cheapest alternative
if more than nine applications were required. With the
stopping rule, this decreased to seven applications (Table 7).
Finally, the EAC requested sight of a further analysis to
reflect some different assumptions, specifically: (1) an
additional five nurse visits for each larvae application, each
with an average duration of 15 min; (2) one home visit for the
Table 7 Threshold analysis of the number of applications of required for Debrisoft to not be cost saving (incremental costs presented
compared with next cheapest alternative—hydrogel)
Debrisoft applications Incremental cost (including switching after stopping rule)
(£)
Incremental cost (excluding switching after stopping rule)
(£)
Home Clinic Home Clinic
3 -211 -99 -377 -153
4 -158 -71 -283 -125
5 -104 -43 -230 v97
6 -51 -15 -176 -69
7 Not cost saving Not cost saving -123 -41
8 Not cost saving Not cost saving -69 -13
9 Not cost saving Not cost saving -16 Not cost saving
10 Not cost saving Not cost saving Not cost saving Not cost saving
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first application of Debrisoft (to reflect the assumption that
nurses have immediate access to Debrisoft at their first
home visit and there is no need to order it); and (3) only two
home visits for the first application of hydrogel (to reflect the
assumption that nurses have immediate access to hydrogel at
their first home visit and there is no need to order it). The
results are shown in Table 6 (‘Committee-requested analy-
sis’). The results showed that Debrisoft remained cost
saving using these alternative assumptions.
In summary, the sponsor concluded that Debrisoft is
cost saving for use in the debridement of wounds compared
with larvae, gauze and hydrogel. This result remained
robust to most analyses conducted by the EAC. Cost sav-
ings ranged from £77 to £222 per patient compared to
hydrogel, from £97 to £347 compared with saline and
gauze, and from £180 to £484 compared with larvae
depending on the assumptions included in the analysis and
whether applied in a home or clinic setting (see Table 6).
The results are driven largely by the requirement for fewer
appointments with Debrisoft than with hydrogel and
gauze in the analysis, and from cheaper product costs for
Debrisoft relative to larvae. All analyses are severely
limited by a lack of comparative data for Debrisoft
compared with hydrogel, larvae or gauze. The threshold
analysis indicates that Debrisoft is likely to be cost saving
for most applications for an endpoint of debridement.
5 NICE Guidance
5.1 Preliminary Guidance
The evidence submitted by the sponsor and the EAC’s
critique of this evidence was presented to the Medical
Technologies Advisory Committee who provided draft
recommendations relating to the Debrisoft monofilament
debridement pad following their meeting in December
2013. These were as follows [37]:
1. ‘‘The case for adopting the Debrisoft monofilament
debridement pad as part of the management of acute or
chronic wounds in the community is supported by the
evidence. The available evidence is limited, but the
likely benefits of using the Debrisoft pad on appropri-
ate wounds are that they will be fully debrided more
quickly, with fewer nurse visits needed, compared with
other debridement methods. In addition, the Debrisoft
pad is convenient and easy to use, and is well tolerated
by patients. Debridement is an important component of
standard woundcare management as described in
Pressure ulcers (NICE clinical guideline 29) [now
replaced by guideline 179] and Diabetic foot problems
(NICE clinical guideline 119)’’ [38, 39].
2. ‘‘The Debrisoft pad is indicated for adults and children
with acute or chronic wounds. The available evidence
is predominantly in adults with chronic wounds
needing debridement in the community. The data
indicate that the device is particularly effective for
chronic sloughy and hyperkeratotic wounds.’’
3. ‘‘The Debrisoft pad is estimated to be cost saving for
complete debridement when compared with other
debridement methods. Cost savings per patient (per
complete debridement) are estimated to be £99, £152
and £484 compared with hydrogel, gauze and bagged
larvae respectively in a community clinic and £222,
£347 and £469 respectively in the home.’’
5.2 Consultation Response
During consultation, NICE received 26 consultation com-
ments from six consultees. As a result of these comments,
the technology description was improved and updated and
the comparator types were clarified, but the recommenda-
tions did not change significantly. Section 4.5 was updated
to state that nurses and other healthcare professionals
should only use Debrisoft after appropriate training in its
indications and safe application.
6 Key Challenges and Learning Points
The Committee agreed with the EAC’s conclusions that there
was a lack of good-quality comparative evidence. The EAC
considered that there was insufficient robust evidence to
demonstrate that Debrisoft is clinically more effective than
other methods for wound healing and wound infections. It
would be better tomeasure outcomes towoundhealing because
this is a clinicallymuchmore important outcomeand there does
not appear to be a strong correlation between achieving com-
plete debridement and subsequent wound healing. In the
VenUS II trial [33, 40], a significant difference in debridement
but no difference in time to healing was found. The sponsor
agreed that there was a lack of evidence on wound healing:
‘‘the complete healing outcome would bring in all
sorts of confounding variables and the comparison of
the benefits between debriding alternatives would be
lost in the impact of the variables to complete wound
healing, i.e. the physiology of the patient, background
disease, effect of arterial status etc.’’
[41]
Also, ‘‘The evidence base is not sufficient at this time to
allow a meaningful analysis of costs or time to complete
healing with debrisoft compared with other debridement
methods in scope (hydrogel or other autolytic dressing, and
cleansing with gauze)’’.
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The EAC noted that the available evidence is mainly in
adults with chronic wounds and accepted that there is little
evidence specific to children or the debridement of acute
wounds. The EAC also noted, from the limited available
evidence, that the Debrisoft pad is particularly suited to
the debridement of sloughy wounds with exudate and
hyperkeratotic skin.
The EAC’s decision to recommend Debrisoft was
based on an evaluation of complete debridement which
suggested that Debrisoft may be cheaper overall than
larvae, hydrogel and debridement with gauze (which is
apparently not used in the UK, according to NICE clinical
experts). The limited evidence available for Debrisoft
meant it was not possible to consider longer-term outcomes
such as time to healing, adverse events, hospital visits, etc.
There is no information on debridement methods currently
being used by nurses or other health professionals in the
community in the UK.
The EAC considered that an RCT of Debrisoft com-
pared with normal current practice in the community is
needed. We suggest that follow-up should be to wound
healing. Outcomes would also include wound infections,
costs and quality of life. It would require that the number of
applications of the debridement technique would need to
reflect the number of applications required in clinical
practice, rather than having the trial restricted to a fixed
number. The RCT that is currently ongoing is not helpful in
this respect because the protocol has no mention of time to
healing as an outcome measure or of wound infection rates
[42]. Also, an audit of current debridement practice in
community health practice in the UK would be very
helpful.
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